Skip to main content

Table 4 Details Of Head-To-Head Studies

From: Intensive therapy and remissions in rheumatoid arthritis: a systematic review

First Author Study Year Design Groups RA Duration Quality Assessments Months Follow-up Treatments
       Allocation Blinding Bias Analysis   Non-Biologic Biologic
Goekoop Ruitermann [45] BeSt 2005 RCT 4 Early Low risk Low risk Low risk 12 Combination DMARDs Infliximab/DMARDs
Heimans [76] Improved 2014 RCT 2 Early Low risk High risk Unclear 12 Triple DMARDs Adalimumab/MTX
Leirisalo-Repo [77] Neo-Fin RA Co 2013 RCT 2 Early Low risk Low risk Low risk 24 Triple DMARDs Infliximab/Triple DMARDs
O’Dell [78] Racat 2013 RCT 2 Est’lishd Low risk Low risk Low risk 12 Triple DMARDs Etanercept/MTX
Scott [79] Tacit 2015 RCT 2 Est’lishd Low risk High risk Indeterminate 12 Combination DMARDs TNF inhibitors/DMARDs
Moreland [80] Tear 2012 RCT 4 Early Low risk Low risk Low risk 24 Triple DMARDs Etanercept/MTX
  1. Abbreviations: RCT Randomised controlled trial, Est’lishd Established, MTX Methotrexate, DMARD Disease modifying anti-rheumatic drugs, TNF Tumour necrosis factor